Cancer Family
Ovarian Epithelial Tumor
CI-CAN-00000305Explore in graph →
Non-malignant271 active trials2 approved drugs26 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000305Explore in graph →
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04787289 | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer | unknown | Phase 2 | 244 | British Columbia Cancer AgencyOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06243185 | Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors | unknown | Phase 2 | 30 | Fengzhi FengOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06241105 |
| Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer |
| unknown |
| Phase 2 |
| 69 |
| Peking Union Medical College HospitalOTHER |
| 1 |
| Feb 5, 2024 |
| clinicaltrials |
| NCT05489926 | A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure | unknown | Phase 2 | 15 | Zhejiang Cancer HospitalOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06055348 | SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer | unknown | Phase 1 / Phase 2 | 112 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT05877911 | Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy | unknown | Phase 2 | 110 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | May 26, 2023 | clinicaltrials |
| NCT03321188 | Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients | unknown | Phase 2 | 20 | Andrea JewellOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05665023 | Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma | unknown | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT04015739 | Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse(BOLD) | unknown | Phase 2 | 74 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05422183 | Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer | unknown | Phase 2 | 20 | Zhongda HospitalOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05385068 | A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi(t) | unknown | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 0 | May 23, 2022 | clinicaltrials |
| NCT02033616 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | unknown | Phase 2 | 99 | Aivita Biomedical, Inc.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05311579 | Niraparib Plus Anlotinib for Recurrent Ovarian Cancer | unknown | Phase 2 | 36 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05310344 | Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 50 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04620954 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-02) | unknown | Phase 1 / Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT04983550 | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC | unknown | Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 85 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT04846842 | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | unknown | Phase 2 | 46 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Apr 19, 2021 | clinicaltrials |
| NCT04068974 | Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer | unknown | Phase 2 | 28 | Peking Union Medical College HospitalOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT02822157 | Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer(CLIO) | unknown | Phase 2 | 160 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT04651946 | Cell-free DNA Methylation for Epithelial Ovarian Cancer | unknown | Phase 2 | 400 | Lei LiOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04376073 | Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer(ANNIE) | unknown | Phase 2 | 40 | Jihong LiuOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04504110 | 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04261465 | NUVOLA TRIAL Open-label Multicentre Study(NUVOLA) | unknown | Phase 2 | 35 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02244502 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | unknown | Phase 1 / Phase 2 | 31 | NovoCure Ltd.INDUSTRY | 4 | Sep 21, 2016 | clinicaltrials |
| NCT02595021 | Total/Subtotal Colectomy in Ovarian Cancer | unknown | Phase 2 | 80 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jul 26, 2016 | clinicaltrials |
| NCT00660101 | Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer | unknown | Phase 1 / Phase 2 | 34 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT02435186 | p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | unknown | Phase 2 | 100 | Shenzhen SiBiono GeneTech Co.,LtdINDUSTRY | 1 | May 6, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Aug 7, 2024source: clinicaltrials